Integration of Chromogenic RNAscope In Situ Hybridization for Target Validation in Drug Discovery
Toxicologic Pathology · 2025-01 · 53 (1) · 21-30
DOI: 10.1177/01926233241311275 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 19.01.2025. Verfasst von Rosanna Win und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Foster City, California, USA. Hauptthemen laut MEDLINE: In Situ Hybridization, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Characterizing the expression of novel targets in normal and diseased tissues is a fundamental component of a target validation data package. Often these targets are presented to the pathology team for assessment with bulk or single-cell RNAseq data and limited to no spatial tissue expression data. In situ hybridization to detect mRNA (RNAscope) is a valuable tool to (1) identify cells that may express the target protein and to corroborate protein expression during immunohistochemical (IHC) assay development or (2) to use as surrogate for single-cell expression IHC when antibodies are not available. Chromogenic RNAscope in situ hybridization (CISH) can be performed on frozen or formalin-fixed, paraffin-embedded (FFPE) tissues. This CISH workflow starts with RNA qualification of the tissue (to assess RNA integrity) by measuring the expression of housekeeping genes. RNA-qualified tissues then undergo CISH for the target in question, and positive CISH signals are quantified in VisioPharm by a combination of color deconvolution, size gating, and dot density thresholding. This RNA workflow can complement IHC or standalone in target validation for spatial characterization of novel targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Foster City, California, USA.
ORCID-Profile: Kelli Boyd
Zitieren
APA
Win, R., Minto, W., Mah, I. K., & Boyd, K. (2025). Integration of Chromogenic RNAscope In Situ Hybridization for Target Validation in Drug Discovery. Toxicologic Pathology, 53(1), 21-30. https://doi.org/10.1177/01926233241311275
Vancouver
Win R, Minto W, Mah IK, Boyd K. Integration of Chromogenic RNAscope In Situ Hybridization for Target Validation in Drug Discovery. Toxicologic Pathology. 2025;53(1):21-30. doi:10.1177/01926233241311275
BibTeX
@article{Win2025,
author = {Win, Rosanna and Minto, Wesley and Mah, In Kyoung and Boyd, Kelli},
title = {Integration of Chromogenic RNAscope In Situ Hybridization for Target Validation in Drug Discovery},
journal = {Toxicologic Pathology},
year = {2025},
volume = {53},
number = {1},
pages = {21--30},
doi = {10.1177/01926233241311275}
}
EUVIMED